title: [Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
authors.forename: Cristina
authors.initials: C
authors.lastname: Martínez Pascual
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Antón Ródenas
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Ortiz Sánchez
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Pons Miñano
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006406:Hematoma / Q000209:etiology; D006467:Hemophilia A / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D001323:Autoantibodies; D001324:Autoantigens; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000069283:Rituximab; D003520:Cyclophosphamide; D005169:Factor VIII; C100416:peginterferon alfa-2a